Español
Questions About Cancer? 1-800-4-CANCER
  • Email

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 26 for your search:
Drug:  Akt inhibitor MK2206
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02675, CDR0000701372, NCCTG-N1087, N1087, U10CA025224, U10CA180821, NCT01369849

2.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-067, NCT01169649

3.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-02270, MDA-2010-0247, CDR0000688457, 2010-0247, 8727, P30CA016672, N01CM00038, N01CM00039, N01CM62202, NCT01239342

4.

Phase: Phase II
Type: Treatment
Status: Closed
Age: Adult
Sponsor: NCI
Protocol IDs: NCI-2011-02619, SWOG-S1005, CDR0000689602, S1005, U10CA180888, U10CA032102, NCT01260701

5.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02648, CDR0000689613, ECOG-E2809, E2809, U10CA021115, U10CA180820, NCT01251861

6.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02892, CDR0000694003, N01CM00039, P30CA016672, MDACC 2010-0242, 2010-0242, 8732, N01CM62202, U01CA062490, NCT01277757

7.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00549, 10-402, 8729, P30CA006516, NCT01283035

8.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02578, CDR0000695056, CHNMC-PHII-108, PhII-108, 8698, N01CM00038, N01CM00071, N01CM62209, P30CA033572, NCT01294306

9.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-02186, 2010-0243, 8731, N01CM00039, NCT01253447

10.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00521, 10-258, 8760, P30CA006516, DFCI-10258, NCT01307631

11.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02581, CDR0000696863, MC1079, 8761, P30CA015083, N01CM00099, MAYO-MC1079, NCT01349933

12.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02974, OSU-10104, CDR0000698451, 8735, N01CM00070, P30CA016058, NCT01425879

13.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110117, 11-C-0117, NCT01333475

14.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01966, CDR0000733948, CALGB-A091104, A091104, N01CM62206, R01CA166978, U10CA031946, U10CA180821, NCT01604772

15.

Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01993, CDR0000737878, SWOG-S1115, S1115, U10CA180888, U10CA032102, NCT01658943

16.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02890, NCI-2011-00275, 2010-0261, 8728, N01CM00039, P30CA016672, N01CM62202, NCT01258998

17.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 91
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_547, MK-2206-003, NCT00848718

18.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_646, MK2206-015, NCT00963547

19.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Other
Protocol IDs: 201001017M, NCT01147211

20.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2011-02612, CDR0000687929, COG-ADVL1013, ADVL1013, U01CA097452, NCT01231919

21.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02550, WCCC-CO-10904, CDR0000688912, CO10904, 8709, P30CA014520, U01CA062491, NCT01245205

22.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10998, NCT01235897

23.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02562, CDR0000690723, 2010-0245, 8739, U01CA062490, U01CA062461, P30CA016672, MDA-2010-0245, NCT01263145

24.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02574, WSU# 2010-109, CDR0000693729, 2010-109, 8747, U01CA062490, U01CA062487, P30CA022453, NCT01281163

25.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8669-049, NCT01295632
1   
New Search